N/A
Completed N=160
Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
Source: ClinicalTrials.gov NCT01027468 ↗Enrolled (actual)
160
Serious AEs
3.1%
Results posted
Feb 2014
Primary outcomePrimary: Vision — 0.16 logMAR
Summary
200 eyes with each subtype of neovascular age-related macular degeneration will be included in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual acuity (BCVA) will be measured using Snellen charts at 6m. Central retinal thickness (CRT) will be measured using Stratus OCT and Cirrus SD-OCT (Zeiss). Data of treatment-naive eyes (group 1) were compared to the data of eyes that had undergone prior treatment with photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide (group 2).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Vision |
0.16 | — |
| PRIMARY CRT (Central Retinal Thickness) |
319 | — |
| SECONDARY Systemic Complications After Treatment |
0; 0; 5; 0 | — |
Eligibility Criteria
Inclusion Criteria
- any subtype of neovascular age-related macular degeneration
- age of 50 years or older
- initial treatment with intravitreal bevacizumab between August 2005 and June 2006
Exclusion Criteria
- previous vitrectomy
- presence of cystoid macular edema without choroidal neovascularization
- Uncontrolled systemic disease
Data sourced from ClinicalTrials.gov (NCT01027468). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.